#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Alpha-1 antitrypsin deficiency Cutaneous calcification Vitamin B12 deficiency Chondrodystrophy Cardiac failure acute Ocular lymphoma Fms-like tyrosine kinase 3 positive Cardiomyopathy Fragile X syndrome Encephalitis autoimmune Bone marrow disorder Lymphangiosarcoma Von Hippel-Lindau disease Neoplasm Thalassaemia beta More trials…

    Learn about Rare Diseases

    Urea cycle disorder – Diagnostics Nodal marginal zone B-cell lymphoma – Life with Disease Proteus syndrome – Trials in Disease Behcet’s syndrome – Life with Disease Nephroblastoma – Trials in Disease Lymphangioma – Basic Information Chronic granulomatous disease – Trials in Disease Ocular melanoma – Life with Disease Chordoma – Basic Information Nodal marginal zone B-cell lymphoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ampreloxetine Zinc Acetate Dihydrate Artemisia Vulgaris Temozolomide Domvanalimab Elacestrant Atorvastatin Calcium Olodaterol Trastuzumab Emtansine Durvalumab Olanzapine Pegipanermin Zelicapavir Glenzocimab Loratadine Sabirnetug [18F] CANAGLIFLOZIN Eteplirsen Sulfamethizole Paxalisib More therapies…

    Learn about Your Condition

    Rectosigmoid cancer Arteriovenous malformation Psychotic disorder Malformation venous Catatonia Acute HIV infection Sleep disorder Thyroid cancer metastatic Apheresis Bipolar I disorder Renal injury Abdominal wall pain Psychological trauma Cortical dysplasia Breast cancer in situ More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. KBC Zagreb

KBC Zagreb

Ulica Mije Kispatica 12, Zagreb, 10000, Croatia

Want to learn more about this study or check if you can participate? Contact us.

  • A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

    Recruiting

    3 1 1
    Investigated Diseases:
    • Immune thrombocytopenia
    Bulgaria Croatia Czechia France Germany Greece +6

  • A Study of ADX-324 to Prevent Attacks in Patients With Hereditary Angioedema

    Recruiting

    3 1
    Investigated Drugs:
    • ADX-324
    Austria Belgium Bulgaria Croatia Czechia France +5

  • A Study of Mezagitamab Compared to Placebo for Adults with Chronic Primary Immune Thrombocytopenia

    Recruiting

    3 1
    Bulgaria Croatia Czechia France Germany Greece +6

  • Study of MT-501 in patients with active Crohn’s Disease or Ulcerative Colitis: A Phase 2 safety and effectiveness trial

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    • Crohn’s disease
    Belgium Bulgaria Croatia Czechia Germany Italy +2

  • Study of xanomeline tartrate and trospium chloride combination for treating agitation in Alzheimer’s disease patients

    Recruiting

    3 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Bulgaria Croatia Greece Portugal Romania Spain

  • Study of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Croatia Czechia Germany Greece Italy The Netherlands +3

  • Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer’s disease patients: Long-term safety evaluation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Bulgaria Croatia Czechia France Greece Hungary +5

  • Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Linvoseltamab
    • Daratumumab
    • Dexamethasone
    Austria Belgium Croatia Czechia Denmark Estonia +10

  • Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

    Recruiting

    3 1 1
    Investigated Drugs:
    • 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
    Belgium Bulgaria Croatia Czechia Estonia Finland +10

  • Study of Plozasiran to prevent acute pancreatitis in adults with severe hypertriglyceridemia

    Recruiting

    3 1
    Investigated Drugs:
    • Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
    Austria Belgium Bulgaria Croatia Czechia Hungary +6
Previous Page
1 2 3 4 … 16
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!